AKAO Achaogen

  0%
Previous Close
Open
Price To Book 1.18
Market Cap
Shares 63,879,995
Volume 0
Short Ratio
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
C-Scape
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Achaogen (AKAO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  2. Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
  3. Achaogen's Bankruptcy Filing, Proposed Sale: What You Need to Know
  4. Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
  5. Edited Transcript of AKAO earnings conference call or presentation 28-Mar-19 8:30pm GMT
  6. Achaogen (AKAO) Upgraded to Buy: Here's Why
  7. Achaogen Inc (AKAO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  8. Achaogen: 4Q Earnings Snapshot
  9. Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  10. The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO
  11. Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019
  12. Does Achaogen, Inc. (NASDAQ:AKAO) Have A High Beta?
  13. Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
  14. Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
  15. Achaogen Announces Closing of $15 Million Underwritten Public Offering
  16. Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences
  17. Achaogen Announces Pricing of $15 Million Underwritten Public Offering
  18. Achaogen Announces Proposed Public Offering of Common Stock
  19. Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield